JP7714162B6 - Ｍｓｈ３活性に関連するトリヌクレオチドリピート伸長障害の処置のための方法 - Google Patents

Ｍｓｈ３活性に関連するトリヌクレオチドリピート伸長障害の処置のための方法

Info

Publication number
JP7714162B6
JP7714162B6 JP2021553755A JP2021553755A JP7714162B6 JP 7714162 B6 JP7714162 B6 JP 7714162B6 JP 2021553755 A JP2021553755 A JP 2021553755A JP 2021553755 A JP2021553755 A JP 2021553755A JP 7714162 B6 JP7714162 B6 JP 7714162B6
Authority
JP
Japan
Prior art keywords
composition
oligonucleotide
oligonucleotides
msh3
trinucleotide repeat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021553755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510041A (ja
JP7714162B2 (ja
JP2022510041A5 (https=
Inventor
ネッサン アンソニー バーミンガム，
ブライアン アール． ベッテンコート，
ピーター エドワード ビアレク，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceuticals USA Inc
Original Assignee
Takeda Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals USA Inc filed Critical Takeda Pharmaceuticals USA Inc
Publication of JP2022510041A publication Critical patent/JP2022510041A/ja
Publication of JP2022510041A5 publication Critical patent/JP2022510041A5/ja
Publication of JP7714162B2 publication Critical patent/JP7714162B2/ja
Application granted granted Critical
Publication of JP7714162B6 publication Critical patent/JP7714162B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021553755A 2018-12-03 2019-12-02 Ｍｓｈ３活性に関連するトリヌクレオチドリピート伸長障害の処置のための方法 Active JP7714162B6 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862774791P 2018-12-03 2018-12-03
US62/774,791 2018-12-03
US201962877142P 2019-07-22 2019-07-22
US62/877,142 2019-07-22
PCT/US2019/064054 WO2020117702A1 (en) 2018-12-03 2019-12-02 Methods for the treatment of trinucleotide repeat expansion disorders associated with msh3 activity

Publications (4)

Publication Number Publication Date
JP2022510041A JP2022510041A (ja) 2022-01-25
JP2022510041A5 JP2022510041A5 (https=) 2022-12-09
JP7714162B2 JP7714162B2 (ja) 2025-07-29
JP7714162B6 true JP7714162B6 (ja) 2025-09-08

Family

ID=70974779

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021553755A Active JP7714162B6 (ja) 2018-12-03 2019-12-02 Ｍｓｈ３活性に関連するトリヌクレオチドリピート伸長障害の処置のための方法

Country Status (7)

Country Link
US (1) US20220072028A1 (https=)
JP (1) JP7714162B6 (https=)
KR (1) KR20210099090A (https=)
AU (1) AU2019394847A1 (https=)
CA (1) CA3121779A1 (https=)
MX (1) MX2021006463A (https=)
WO (2) WO2020117702A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210355491A1 (en) * 2020-04-20 2021-11-18 University Of Massachusetts Oligonucleotides for msh3 modulation
US20230313185A1 (en) * 2020-05-08 2023-10-05 Triplet Therapeutics, Inc. Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity
AR122534A1 (es) 2020-06-03 2022-09-21 Triplet Therapeutics Inc Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
EP4247392A4 (en) * 2020-06-03 2025-10-08 Takeda Pharmaceuticals Usa Inc METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY
WO2021252799A2 (en) * 2020-06-11 2021-12-16 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing msh3 expression
US20240263179A1 (en) * 2021-06-04 2024-08-08 Takeda Pharmaceuticals U.S.A., Inc. Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity
WO2023168304A2 (en) * 2022-03-02 2023-09-07 Triplet Therapeutics, Inc. Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity
WO2024251211A1 (en) * 2023-06-06 2024-12-12 Revir Therapeutics, Inc. Compositions, methods, and systems for modulating splicing of msh3

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010369A1 (en) * 1997-08-28 1999-03-04 Thomas Jefferson University Compositions, kits, and methods for effecting adenine nucleotide modulation of dna mismatch recognition proteins
US20050244851A1 (en) * 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
WO2008157747A1 (en) * 2007-06-21 2008-12-24 The Jackson Laboratory Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
US10202599B2 (en) * 2011-08-11 2019-02-12 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
WO2015171918A2 (en) * 2014-05-07 2015-11-12 Louisiana State University And Agricultural And Mechanical College Compositions and uses for treatment thereof
EP3806850A2 (en) * 2018-06-15 2021-04-21 Ideaya Biosciences, Inc. Methods of inhibiting proliferative cells
AR122534A1 (es) * 2020-06-03 2022-09-21 Triplet Therapeutics Inc Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
US20240263179A1 (en) * 2021-06-04 2024-08-08 Takeda Pharmaceuticals U.S.A., Inc. Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Iyer RR. et al.，Annu Rev Biochem，2015年，Vol. 84，pp. 199-226
小比賀 聡 ほか，アンチセンス核酸医薬のデザイン戦略，日薬理誌，2016年，Vol. 148，pp. 100-104

Also Published As

Publication number Publication date
WO2020117703A1 (en) 2020-06-11
MX2021006463A (es) 2021-09-28
JP2022510041A (ja) 2022-01-25
JP7714162B2 (ja) 2025-07-29
WO2020117702A1 (en) 2020-06-11
CA3121779A1 (en) 2020-06-11
AU2019394847A1 (en) 2021-07-22
US20220072028A1 (en) 2022-03-10
KR20210099090A (ko) 2021-08-11

Similar Documents

Publication Publication Date Title
JP7714162B6 (ja) Ｍｓｈ３活性に関連するトリヌクレオチドリピート伸長障害の処置のための方法
KR20230033651A (ko) Serpina1의 adar-매개 편집을 위한 방법 및 조성물
US20220056455A1 (en) Compositions and methods for the treatment of kcnt1 related disorders
WO2023278410A1 (en) Methods and compositions for adar-mediated editing
US20250327073A1 (en) Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with msh3 activity
US20220033814A1 (en) Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh1 activity
US12485136B2 (en) Methods for the treatment of trinucleotide repeat expansion disorders associated with MLH3 activity
US20240263179A1 (en) Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity
EP4341405A1 (en) Methods and compositions for adar-mediated editing
AU2020394627B2 (en) Methods for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
US20250002912A1 (en) Compositions and methods for the treatment of pcdh19 related disorders
US20230041178A1 (en) Methods for the treatment of trinucleotide repeat exapnsion disorders associated with ogg1 activity
WO2024182578A1 (en) Oligonucleotides for rna editing
CN118922543A (zh) 用于治疗pcdh19相关疾患的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250425

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250527

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250626

R150 Certificate of patent or registration of utility model

Ref document number: 7714162

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150